Zea AH - Search Results

1

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL. Fenton RG, et al. Among authors: zea ah. J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74. doi: 10.1097/00002371-199609000-00006. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8941876 Clinical Trial.

2

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.

Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Gause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL. Curti BD, et al. J Clin Oncol. 1998 Aug;16(8):2752-60. doi: 10.1200/JCO.1998.16.8.2752. J Clin Oncol. 1998. PMID: 9704728 Clinical Trial.

3

Alterations in T cell receptor and signal transduction molecules in melanoma patients.

Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, et al. Zea AH, et al. Clin Cancer Res. 1995 Nov;1(11):1327-35. Clin Cancer Res. 1995. PMID: 9815928

4

Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.

Gratama JW, Zea AH, Bolhuis RL, Ochoa AC. Gratama JW, et al. Among authors: zea ah. Cancer Immunol Immunother. 1999 Aug;48(5):263-9. doi: 10.1007/s002620050574. Cancer Immunol Immunother. 1999. PMID: 10478643 Free PMC article.

5

Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.

Franco JL, Ghosh P, Wiltrout RH, Carter CR, Zea AH, Momozaki N, Ochoa AC, Longo DL, Sayers TJ, Komschlies KL. Franco JL, et al. Among authors: zea ah. Cancer Res. 1995 Sep 1;55(17):3840-6. Cancer Res. 1995. PMID: 7641202

6

Mechanisms of tumor evasion from the immune response.

Rodríguez PC, Zea AH, Ochoa AC. Rodríguez PC, et al. Among authors: zea ah. Cancer Chemother Biol Response Modif. 2003;21:351-64. doi: 10.1016/s0921-4410(03)21018-8. Cancer Chemother Biol Response Modif. 2003. PMID: 15338755 Review.

7

IL-4 inhibits IL-2-induced tumoricidal activity and secretory functions of human monocytes. Modulation of IL-2 binding and IL-2 receptor beta gamma chain expression.

Bosco MC, Pulkki K, Rowe TK, Zea AH, Musso T, Longo DL, Varesio L, Espinoza-Delgado I. Bosco MC, et al. Among authors: zea ah. J Immunol. 1995 Aug 1;155(3):1411-9. J Immunol. 1995. PMID: 7636206

8

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.

Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Ochoa AC, et al. Among authors: zea ah. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s. doi: 10.1158/1078-0432.CCR-06-2197. Clin Cancer Res. 2007. PMID: 17255300 Review.

9

Mechanisms of tumor evasion.

Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Campoli M, et al. Among authors: zea ah. Cancer Treat Res. 2005;123:61-88. doi: 10.1007/0-387-27545-2_3. Cancer Treat Res. 2005. PMID: 16211866 Review.

10

Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.

Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, et al. Finke JH, et al. Among authors: zea ah. Cancer Res. 1993 Dec 1;53(23):5613-6. Cancer Res. 1993. PMID: 8242613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page